Andrew Cridland

WaveBreak (formerly Wren Therapeutics)

WaveBreak (www.WaveBreakTx.com) is a biopharmaceutical company focused transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson's disease, Alzheimer's disease, and ALS. WaveBreak was previously Wren Therapeutics.